KAI-4169 meets hyperparathyroidism endpoint

KAI Pharmaceuticals Inc. (South San Francisco, Calif.) said KAI-4169 met the primary endpoint in a Phase II trial to treat secondary hyperparathyroidism. Thrice-weekly 5 and 10 mg IV doses of the product given during hemodialysis each significantly reduced mean parathyroid hormone (PTH) levels from baseline to week four vs. placebo (p<0.05 for both). The double-blind, dose-escalation, U.S. trial enrolled patients with chronic kidney disease-mineral and bone disorder (CKD-MBD). KAI-4169 is a peptide calcimimetic that acts on the parathyroid gland to reduce production of PTH. ...